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Abstract
Background: Exosomes are released from multiple cell types, contain protein and RNA species, and have been
exploited as a novel reservoir for disease biomarker discovery. They can transfer information between cells and
may cause pathology, for example, a role for exosomes has been proposed in the pathophysiology of Alzheimer’s
disease. Although studied in several biofluids, exosomes have not been extensively studied in the cerebrospinal
fluid (CSF) from humans. The objective of this study was to determine: 1) whether human CSF contains exosomes
and 2) the variability in exosomal protein content across individuals.
Methods: CSF was collected from 5 study participants undergoing thoraco-abdominal aortic aneurysm repair
(around 200 - 500 ml per participant) and low-density membrane vesicles were concentrated by ultracentrifugation.
The presence of exosomes was determined by western blot for marker proteins, isopycnic centrifugation on a
sucrose step gradient and transmission electron microscopy with immuno-labelling. Whole protein profiling was
performed using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR).
Results: Flotillin 1 and tumor susceptibility gene 101 (TSG101), two exosomal marker proteins, were identified in
the ultracentrifugation pellet using western blot. These markers localized to a density consistent with exosomes
following isopycnic centrifugation. Transmission electron microscopy visualized structures consistent with exosomes
in size and appearance that labelled positive for flotillin 1. Therefore, the pellet that resulted from
ultracentrifugation of human CSF contained exosomes. FT-ICR profiling of this pellet was performed and 84-161
ions were detected per study participant. Around one third of these ions were only present in a single study
participant and one third were detected in all five. With regard to ion quantity, the median coefficient of variation
was 81% for ions detected in two or more samples.
Conclusions: Exosomes were identified in human CSF and their proteome is a potential new reservoir for
biomarker discovery in neurological disorders such as Alzheimer’s disease. However, techniques used to
concentrate exosomes from CSF need refinement to reduce variability. In this study we used relatively large
starting volumes of human CSF, future studies will focus on exosome isolation from smaller ‘real life’ clinical
samples; a key challenge in the development of exosomes as translational tools.
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Exosomes are lipid and protein rich vesicles that are
formed as part of the intra-cellular endosomal pathway
[1]. During maturation of early endosomes into late
endosomes within the cell, the endosomal limiting
membrane undergoes invagination forming intra-luminal
vesicles. A subset of endosomes fuse with the plasma
membrane and their intra-luminal vesicles are released
into the extracellular space where they are termed exo-
somes. Exosomes have physicochemical properties that
distinguish them from other cell-derived vesicles. They
are 20-100 nm in size [2], appear cup-shaped when
visualised by transmission electron microscopy (TEM)
[3], have a density of 1.10 to 1.19 g/ml [4,5] and contain
characteristic proteins that are central to their produc-
tion [6]. Such proteins include flotillin-1, which is asso-
ciated with lipid rafts that act as the location for
exosomal formation [6] and tumor susceptibility gene
101 (TSG101), a component of the Endosomal Sorting
Complex Required for Transport (ESCRT) protein
group that mediates exosome assembly [7].
Exosomes represent a novel reservoir for biomarker
discovery because they contain protein, messenger RNA
and microRNA that has been demonstrated to change
with the disease state of the affected organ [8,9]. To
date, in the nervous system, most research into exo-
somes has been in vitro, for example, primary cultures
of rat cortical neurons [10], differentiated cortical neu-
rons [11] and glial cells [12,13] have been demonstrated
to release exosomes. Using TEM and laser correlation
spectroscopy, structures with a similar morphology to
exosomes have been reported in human cerebrospinal
fluid (CSF) [14,15]. The centrifugation fraction that
expressed these structures on TEM contained the ras-
related protein Ral-A, a protein that has been associated
with exosomes [14,16].
In addition to being a source of biomarkers there is
evidence that exosomes may mediate neurological dis-
ease. In Alzheimer’s disease (AD), cleavage of amyloid
precursor protein by the enzyme b-secretase occurs in a
subset of endosomes and a fraction of the Ab protein is
released into the extracellular milieu in association with
exosomes [17,18]. Furthermore, exosomal markers are
enriched in amyloid plaques from the brains of mice
[19] and the post-mortem brains of patients with AD
[17]. This suggests that exosomal transfer of amyloid
into the extra-cellular space may be an important path-
way in the development of AD. Extracellular accumula-
tion of tau protein is another pathological hallmark of
AD. This protein is secreted in exosomes and an ele-
vated CSF tau concentration in patients with AD may
be due to exosomal release from cells [20]. The protein
a-synuclein is a mediator of neurodegeneration in
Parkinson’s disease (PD) that is released from cultured
cells in exosomes [21]. Application of a-synuclein con-
taining exosomes onto cells induced cell death; consis-
tent with exosomes being mediators of inter-cellular
signalling, a physiological mechanism that has been
reported in other organs [22,23]. Prion diseases are
infectious neurodegenerative disorders and there is in
vitro evidence that exosomes may represent the
mechanism of prion protein transfer between cells
[24,25]. In sheep CSF, prion proteins are enriched in
exosomes [26]. Given their potential as a reservoir for
biomarker discovery, and as mediators of neurological
disease, the first objective of the present study was to
confirm that human CSF contains exosomes.
The protein composition of a complex biofluid can be
investigated using mass spectrometry [27-30]. This
approach allows for an unbiased assessment of the pro-
teome without the need for prior knowledge of protein
identities. At present, there is no method for isolating
exosomes from a complex biofluid without a degree of
‘contamination’ from non-exosomal proteins. Using
quantitative mass spectrometry the second objective was
to profile the composition of the human CSF sub-frac-
tion that contained exosomes to give an indication of
the variability and so provide information for planning
future biomarker discovery studies.
Methods
Study participants and sample collection
CSF was collected from 5 patients undergoing thoraco-
abdominal aortic aneurysm repair. None of the patients
had a history of neurological illness. This study was
approved by NHS Lothian research ethics committee
and prospective informed consent was obtained from all
patients. This patient group was chosen because they
have a CSF drain inserted peri-operatively as part of
routine clinical management and large volumes of CSF
are available for study (around 200 - 500 ml). Men were
recruited to this study because female sex hormones
may alter exosome release. The CSF was carefully
inspected for evidence of blood contamination before
collection. Protease inhibitors and preservative (final
concentration: 3.34 mM sodium azide, 0.5 mM phenyl-
methylsulphonyl fluoride, 20 μM leupeptin) were added
to the collected CSF. The collected CSF was stored in
aliquots at -80°C before use [31].
Exosome concentration
After thawing, the CSF was vigorously vortexed then
centrifuged at 15,000 × g for 10 minutes to pellet any
shed cells, large membrane fragments and other debris.
The supernatant was then centrifuged at 200,000 × g for
60 minutes. The pellet was resuspended in phosphate
Street et al. Journal of Translational Medicine 2012, 10:5
http://www.translational-medicine.com/content/10/1/5
Page 2 of 7buffered saline (PBS) and then re-centrifuged at 200,000
× g for 60 minutes before final resuspension in PBS.
The protein content of the exosomal fraction was deter-
mined using the BCA protein assay kit (Pierce, Rock-
ford, IL, USA).
Western blotting
Samples were solubilised with Laemmli sample buffer
and separated on a 1D SDS-PAGE gel before transfer to
polyvinylidene fluoride (PVDF, Invitrogen, Paisley, UK)
membrane. The membrane was probed with the follow-
ing primary antibodies: mouse anti-human flotillin-1
(BD Biosciences, Franklin Lakes, USA) and mouse anti-
human TSG101 (Abcam, Cambridge, UK).
Sucrose density gradient
Sample was diluted into the top fraction of a step gradi-
ent comprising layers of 2, 1.3, 1.16, 0.8, 0.5 and 0.25 M
sucrose. The gradients were centrifuged for 2.5 hours at
100,000 × g. Six fractions were collected from the gradi-
ent and stored for density determination on a DMA 35
N density meter (Anton Paar, Hertford, UK) and for
western blot analysis.
Electron microscopy
The exosomal fraction was mixed 1:1 with 4% parafor-
maldehyde. A drop of this solution was then placed on
a Petri dish and a formvar-coated 200-mesh gold grid
floated on top for 20 minutes. The grid was washed in
PBS before low and high molecular weight blocking
using 0.05 M glycine/PBS and 1% BSA/PBS, respectively.
The grid was re-washed and transferred to a 1:200 dilu-
tion of the anti-flotillin-1 antibody or the isotype control
in 0.02% Triton X-100 PBS for 45 minutes at room tem-
perature. The grid was then incubated with a 10 nm
gold conjugated anti-mouse IgG antibody (Sigma
Aldrich, Gillingham, UK) for 60 minutes at room tem-
perature. The grid was washed again and incubated with
1% glutaraldehyde for 5 minutes. The grid was washed
and then contrasted and embedded with 0.5% uranyl
acetate/2% methyl cellulose. Excess fluid was removed,
the grid allowed to air dry and then the grid was exam-
ined on a Philips CM120 BioTwin transmission electron
microscope.
Proteomic analysis
Proteomic studies were performed on the ultra-centrifuga-
tion pellet from each study participant, with each pellet
being analysed in duplicate as per previous studies [32].
Initial studies demonstrated a high concentration of
immunoglobulins in CSF. Therefore, after ultra-centrifuga-
tion, the immunoglobulins were depleted from the sam-
ples by incubation with protein G agarose beads (Fluka,
Gillingham, UK). Depletion of immunoglobulin was
confirmed by western blotting using an anti immunoglo-
bulin primary antibody (AbD Serotec, Kidlington, UK).
After immunoglobulin depletion, the presence of exo-
somes was confirmed by western blotting for flotillin-1.
FT-ICR mass spectrometry
The proteins present in the ultra-centrifugation pellet
were separated from the lipid components using a
chloroform/methanol precipitation [33]. Following
resuspension of the chloroform/methanol precipitation
pellet, separation was on a UltiMate 3000 series HPLC
instrument (Dionex, Sunnyvale, CA, USA) equipped
with a PS-DVB monolithic column (500 μm×5c m ) .
Mass spectra were acquired on a 12T Apex Ultra Qe
FT-ICR mass spectrometer (Bruker Daltonics, Billerica,
MA, USA), equipped with a electrospray source. Instru-
ment control was achieved using Apex control. Each
analysis was the average of 2 spectra. Ions were detected
between m/z 200 and 3000, yielding 1 Mword time-
domain transients.
The mass spectrometry data was processed using the
DataAnalysis (Bruker Daltonics, Billerica, MA, USA) soft-
ware package version 4 SP4. The Progenesis LC-MS v2.6
software package (Non-linear Dynamics, Newcastle upon
Tyne, UK) was used for the quantitative mass spectrome-
try. This package matched the peaks from the ion chroma-
tograms of our 5 study participants by the elution time
and m/z ratio. The quality of the matching was checked
manually. This matching process allowed determination of
the number of samples which contained a given protein or
peptide. The ion current was integrated over the elution
window, then normalised against the total ion current of
the chromatogram, and comparative quantitation of the
abundance of an ion detected in 2 or more samples was
calculated. Data analysis was performed in the python lan-
guage with the Scipy http://www.scipy.org, and Matplotlib
[34] packages used for general statistical analysis and data
visualisation respectively.
Results
CSF was collected from 5 patients whose demographics
are presented in Table 1. Ultracentrifugation of human
Table 1 Demographics and comorbidities for the 5
patients.
Patient Sex Age Comorbidity
1 M 67 IHD and hypotension
2 M 72 Hypertension and CKD
3 M 77 Hypertension
4 M 70 DM and IHD
5 M 68 None
Abbreviations; IHD, Ischaemic heart disease; CKD, Chronic kidney disease; DM,
Diabetes mellitus.
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Following separation of the proteins in the pellet there
were bands unique to the ultracentrifuge pellet sample,
s u g g e s t i n gt h a tt h i sm a yb ead i s t i n c tp r o t e o m e( F i g u r e
1b). To investigate whether this proteome was, at least
in part, exosomal in origin, the presence of established
exosomal markers was determined using western blot
for flotillin-1 and TSG101. This demonstrated enrich-
ment of both proteins in the pellet compared with
unfractionated CSF (Figure 1c). To further confirm that
flotillin-1 and TSG101 were located in exosomes, iso-
pycnic centrifugation on a sucrose step gradient was
performed. Flotillin-1 and TSG101 localised to fractions
3 and 4, which corresponded to a density of 1.10-1.14 g.
cm
3 (Figure 1d). Isopycnic centrifugation was performed
in 4 subjects and the exosomal markers were consis-
tently localized to the density range 1.10-1.18 g.cm
-3
(data not shown).
TEM revealed a number of structures of exosomal size
and appearance (Figure 2a) but there were also struc-
tures of a larger size, as has been previously reported
[14]. To confirm that exosomes were present, labelling
with an anti-flotillin 1 antibody was performed and cup-
shaped structures of the characteristic size for exosomes
w e r ef o u n dt ob i n dg o l dn a n o p a r t i c l e s( F i g u r e2 b ) .
When the flotillin-1 antibody was replaced with an
isotype control antibody, although structures of the
characteristic size and appearance could be identified, a
significantly reduced number of bound gold nanoparti-
cles were present (gold nanoparticle binding (mean ±
SD): flotillin-1 antibody 0.6 ± 0.4 particles per exosome;
isotype control 0.1 ± 0.1 particles per exosome, p =
0.006 by t-test).
Profiling using FT-ICR MS detected between 84-161
ions in the 5 ultracentrifugation pellets (Figure 3a). The
range of molecular weights were 636-33467 Da. Coeffi-
cient of variation (CV) for the retention time was 0.13%,
facilitating the automated alignment performed by the
Progenesis software. 66 ions were present in all 5 parti-
cipants and 64 ions were only found in a single study
participant (Figure 3b). For ions detected in two or
more samples, the variability in the integrated ion cur-
rent (a measure of an ion’s abundance in a particular
sample) across study participants was 68% at the 25
th
percentile (25% of ions had a CV < 68%) and the med-
ian was 81% (Figure 3c). Among the ten most abundant
ions the maximum variation was 13.9% (Table 2).
Figure 1 A) The pellet resulting from ultracentrifugation of
human CSF contained protein. The amount of protein is
expressed as per ml of CSF. Samples 1 - 5 are from 5 different study
participants. B) The size distribution of protein was different in the
pellet resulting from ultracentrifugation of human CSF (CSF pellet)
compared with uncentrifuged CSF (whole CSF). C) Western blots for
flotillin-1 and TSG-101 on the ultracentrifugation pellet (P) and
supernatant (S) from CSF collected from 3 study participants (1-3).
Both exosomal markers were enriched in the pellets in comparison
to the supernatants. D) Western blot for flotillin-1 and TSG101 on
fractions obtained following isopycnic centrifugation. The exosomal
markers were present in fractions corresponding to a density of
1.10-1.14 g.cm
-3 .
Figure 2 A) Transmission electron micrographs of embedded
and negatively stained human CSF. Several structures of the
characteristic size and appearance for exosomes are highlighted by
arrows. B) Transmission electron micrographs of human CSF
exosomes incubated with an anti-flotillin-1 antibody and then a
gold nanoparticle tagged secondary antibody. A structure with the
appearance of an exosome labelled by 2 gold nanoparticles is
demonstrated in the figure.
Figure 3 Ions detected following FT-ICR MS on the pellet that
resulted from ultracentrifugation of human CSF. A) The number
of ions detected in each sample. Sample 1 - 5 are from 5 different
study participants B) The number of ions detected in multiple
samples. C) Histogram for the coefficient of variation of ions
detected in 2 or more of the 5 CSF ultracentrifugation pellets.
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Discussion
Release of exosomes from a variety of different neuronal
cell lines has been described [10] and there is evidence
that exosomes may be involved in the pathogenesis of
neurological disease [17,18]. Despite the potential
importance of exosomes in the context of the central
nervous system and neurological diseases the presence
of exosomes in human CSF has not been confirmed. In
t h ep r e s e n ts t u d yw eh a v ed e m o n s t r a t e dt h a te x o s o m e s
are present in the CSF of humans. The evidence for
exosome presence takes three forms: 1) proteins widely
documented to be present within exosomes are enriched
in the ultracentrifugation pellet in comparison with the
supernatant; 2) following separation of the ultracentrifu-
gation pellet based on density, the markers localise to a
density range which is consistent with these proteins
being contained in exosomes; 3) direct visualisation of
the resuspended membrane vesicles from the ultracen-
trifugation pellet revealed the presence of structures
matching exosomes in size and shape. In a further
experiment these structures were demonstrated to con-
tain the exosomal marker flotillin-1.
Exosomes are membrane bound vesicles formed
within the cellular endosomal system [1] and released
into a wide range of human biofluids such as blood [35],
urine [2], ascites [36], amniotic fluid [37], pleural fluid
[38] and saliva [39,40]. They contain protein, messenger
RNA and microRNA [41] from their cell of origin which
changes with cell activation and injury [42] and repre-
sents a reservoir for disease biomarker discovery. Exo-
somes also mediate inter-cellular communication by
transferring protein and RNA species between cells and
altering the recipient cell phenotype [22,23]. For exam-
ple, in the immune system, exosomes transfer
microRNA from T-lymphocytes to antigen presenting
cells and this microRNA modulates gene expression in
the recipient cells [43]. The ability of the exosome to
transfer information has been exploited to deliver sys-
temically administered, short interfering RNA to the
brain with a high degree of tissue-specificity [44]. In the
present study we confirm the presence of exosomes in
human CSF. This ‘proof of concept’ study should stimu-
late investigation of the differences between disease and
control in terms of the exosome composition. Exosomes
have been demonstrated to play a role in the pathogen-
esis of AD and an investigation of CSF exosomes from
patients with AD is a potential next study. However,
there are important caveats that need consideration
before such a study can be successfully performed. In
our study we recruited patients undergoing thoraco-
abdominal aortic aneurysm repair because this allowed
access to large CSF volumes. Such volumes will not be
available from patients with AD and so there is a need
to refine our techniques for exosome isolation using
approaches such as isopycnic centrifugation, ultrafiltra-
tion [45] or immunoaffinity [46]. In comparison to pro-
tein, the study of RNA has the advantage that
amplification techniques are available and this may
allow human CSF exosomal RNA to be studied with
routinely available CSF volumes. As proof of concept,
exosomes in human amniotic fluid, saliva and urine
have been demonstrated to contain sufficient RNA to
determine the presence of single nucleotide polymorph-
isms [37]. Finally, as the cellular origin of the exosomes
is unknown, we do not know whether the cells affected
by AD actually release exosomes into human CSF.
The human CSF exosomes were concentrated by
ultra-centrifugation. This technique does not completely
isolate exosomes from other components of a complex
biofluid and non-exosomal proteins may still be present.
To reduce this contamination, immunoglobulins were
Table 2 The ten most abundant ions in the pellet that resulted from ultracentrifugation of human CSF as measured by
FT-ICR MS.
m/z Charge Average Abundance Coefficient of variation (%) Retention Time (min)
Retention 1 Retention 2 Retention 3 Retention 4 Retention 5
659.5042 2 84905.83 9.48 32.35 32.34 32.44 32.41 32.39
637.4901 2 79016.43 8.88 32.35 32.34 32.44 32.41 32.39
681.5181 2 73538.83 10.40 32.35 32.34 32.44 32.41 32.39
615.4762 2 71518.13 7.83 32.28 32.28 32.38 32.35 32.33
703.5339 2 70627.72 10.75 32.42 32.40 32.51 32.47 32.44
593.462 2 64351.47 9.18 32.28 32.28 32.38 32.35 32.33
571.4479 2 51233.77 10.47 32.22 32.21 32.31 32.29 32.28
725.5471 2 45044.52 9.20 32.42 32.40 32.51 32.47 32.44
549.4341 2 41728.51 8.51 32.22 32.21 32.31 32.29 32.28
527.42 2 29260.44 13.92 32.15 32.15 32.24 32.23 32.22
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filing of our 5 study participants was performed to
begin the process of understanding the variability
between ultracentrifugation pellets prepared from differ-
ent people. When mass spectrometer generated ion cur-
rents are being compared, specific tags can be used to
label proteins from different proteomes. The two most
commonly used methods are isotope-coded affinity tags
(ICAT) and isobaric tag for relative and absolute quanti-
fication (iTRAQ)[47]. Both these techniques involve
additional cost, experimental steps and, potentially, the
inclusion of additional errors. Also, comparison across 5
proteomes would be difficult due to limited numbers of
distinct labels. Our approach was label-free, and this
was possible because FT-ICR MS provided extremely
high accuracy in the m/z ratios, ensuring confidence in
matching ions across samples [48]. We only detected
low molecular weight ions, that probably represent poly-
peptide species and small proteins, because larger spe-
cies were deliberately excluded from entering the
chromatography column. This was necessary to prevent
large proteins attaching and failing to elute. Around a
third of ions were present in all 5 study participants but
a similar number were only detected in a single sample.
For ions that were detected in 2 or more samples, the
coefficients of variation were approximately comparable
to similar studies including one in the whole CSF [49].
T h ei o n st h a tw e r eo n l yd e t e c t e di ns i n g l es a m p l e sm a y
represent technical variability in sample preparation,
contamination from non-exosomal proteins or true
variability in exosomal composition. Improved techni-
ques for exosome isolation may reduce the variability in
the samples. In the present study the ultra-centrifuga-
tion pellet from each study participant was analysed in
duplicate, the same number of technical replicates as
performed in other studies that have used mass spectro-
metry to quantify differences in human CSF protein
abundance [32]. Increasing the number of biological and
technical replicates may increase the ion coverage and
improve confidence that an observed difference in an
ion represents a true difference in the exosomal
proteome.
Conclusions
We have identified exosomes in the CSF from humans.
These cell-derived particles represent a new reservoir
for neurological disease protein and RNA biomarker dis-
covery. However, the techniques used to concentrate
exosomes from CSF need refinement to improve the
quality of exosome isolation. In this study we used rela-
tively large starting volumes of human CSF, future stu-
dies will focus on exosome isolation from smaller ‘real
life’ clinical samples; a key challenge in the development
of exosomes as translational tools.
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